Gemtuzumab ozogamicin, a CD33 specific ADC, for relapsed acute myeloid leukemia13, 14 and brentuximab vedotin, a CD30 specific ADC, have been commonly used in clinical practice and achieved an 86% overall response rate in patients with relapsed anaplastic large cell lymphoma (ALCL)15. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.